RevMed is using ASCO as a chance to spotlight the full data from the phase 3 trial of daraxonrasib,...
ASCO: RevMed confident in Ras leadership as rivals square up
RevMed is using ASCO as a chance to spotlight the full data from the phase 3 trial of daraxonrasib, which took the world by storm earlier this year.
Author: Fierce Biotech
Read Original Article